2023
End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting. Journal Of Clinical Oncology 2023, 41: 4729-4738. PMID: 37339389, PMCID: PMC10602547, DOI: 10.1200/jco.22.02180.Peer-Reviewed Original ResearchConceptsSystemic treatmentEnd of lifeWhite patientsBlack patientsOdds ratioLarge real-world populationPractice settingsTreatment ratesPatient-level factorsEmergency department useIntensive care unitReal-world populationDay of deathImmunotherapy eraSystemic therapyOncologic treatmentCare unitDeidentified databaseDepartment usePatient raceInsurance typeMetastatic cancerDownstream careMedicaid patientsHigher oddsRacial inequality in COVID-treatment and in-hospital length of stay in the US over time
Althouse B, Baker C, Smits P, Gratzl S, Lee R, Cartwright B, Simonov M, Wang M, Stucky N. Racial inequality in COVID-treatment and in-hospital length of stay in the US over time. Frontiers In Public Health 2023, 10: 1074775. PMID: 36711416, PMCID: PMC9876573, DOI: 10.3389/fpubh.2022.1074775.Peer-Reviewed Original Research
2022
Evaluation of the Impact of HIV Serostatus on the Hepatitis C Virus Care Cascade and Injection Drug Use Among Persons Initiating Medication Treatment for Opioid Use Disorder
Lier A, Vander Wyk B, Di Paola A, Springer S. Evaluation of the Impact of HIV Serostatus on the Hepatitis C Virus Care Cascade and Injection Drug Use Among Persons Initiating Medication Treatment for Opioid Use Disorder. Open Forum Infectious Diseases 2022, 9: ofac624. PMID: 36467300, PMCID: PMC9709708, DOI: 10.1093/ofid/ofac624.Peer-Reviewed Original ResearchOpioid use disorderHepatitis C virusHCV treatment ratesHIV serostatusUse disordersHepatitis C virus (HCV) care cascadeHCV viral load testingTreatment ratesHCV treatment uptakeProspective cohort studyInjection drug useViral load testingGreater reductionDrug use frequencyHCV testingCare cascadeHCV antibodiesHIV screeningCohort studyHIV statusTreatment uptakeEntire cohortMedication treatmentC virusSerostatusSex Differences in Endovascular Therapy for Ischemic Stroke: Results From the Get With The Guidelines–Stroke Registry
Demel S, Reeves M, Xu H, Xian Y, Mac Grory B, Fonarow G, Matsouaka R, Smith E, Saver J, Schwamm L. Sex Differences in Endovascular Therapy for Ischemic Stroke: Results From the Get With The Guidelines–Stroke Registry. Stroke 2022, 53: 3099-3106. PMID: 35880521, DOI: 10.1161/strokeaha.122.038491.Peer-Reviewed Original ResearchConceptsEndovascular therapyIschemic strokeHealth Stroke Scale scoreTreatment ratesGuidelines-Stroke hospitalsGuidelines-Stroke registryStroke Scale scoreAcute ischemic strokeSex differencesLarge vessel occlusionMultivariable regression analysisIschemic stroke dischargesEVT useHospital deathHospital mortalityASA guidelinesVessel occlusionOdds ratioScale scoreStroke dischargesSignificant sex differencesWomenNational InstituteMenStatistical adjustment
2021
National Trends in Racial and Ethnic Disparities in Antihypertensive Medication Use and Blood Pressure Control Among Adults With Hypertension, 2011–2018
Lu Y, Liu Y, Dhingra LS, Massey D, Caraballo C, Mahajan S, Spatz ES, Onuma O, Herrin J, Krumholz HM. National Trends in Racial and Ethnic Disparities in Antihypertensive Medication Use and Blood Pressure Control Among Adults With Hypertension, 2011–2018. Hypertension 2021, 79: 207-217. PMID: 34775785, DOI: 10.1161/hypertensionaha.121.18381.Peer-Reviewed Original ResearchConceptsAntihypertensive medication usePoor hypertension controlOverall treatment rateLow control rateHypertension controlHypertension awarenessMedication useControl rateHispanic individualsEthnic differencesTreatment ratesBlack individualsGuideline-recommended medicationsBlood pressure controlWhite individualsNutrition Examination SurveyLow awareness rateAntihypertensive medicationsHypertensive peopleExamination SurveyIntensive medicationNational HealthAwareness rateEthnic disparitiesPressure controlPorcine Xenograft and Epidermal Fully Synthetic Skin Substitutes in the Treatment of Partial-Thickness Burns: A Literature Review
Haller H, Blome-Eberwein S, Branski L, Carson J, Crombie R, Hickerson W, Kamolz L, King B, Nischwitz S, Popp D, Shupp J, Wolf S. Porcine Xenograft and Epidermal Fully Synthetic Skin Substitutes in the Treatment of Partial-Thickness Burns: A Literature Review. Medicina 2021, 57: 432. PMID: 33946298, PMCID: PMC8146423, DOI: 10.3390/medicina57050432.Peer-Reviewed Original ResearchConceptsPorcine xenograftsPartial-thickness burnsPrimary endpointStudy's primary endpointComplete wound healingLow infection rateSynthetic skin substituteLarger TBSASkin graftsXenograft studiesPRISMA guidelinesHealing timeThickness burnsSuprathelInfection rateSystematic reviewXenograftsTreatment ratesPartial thicknessWound healingDonor siteSignificant differencesTreatmentLow necessitySkin substitutes
2020
Acute ischemic stroke: improving access to intravenous tissue plasminogen activator
Turner A, Schwamm L, Etherton M. Acute ischemic stroke: improving access to intravenous tissue plasminogen activator. Expert Review Of Cardiovascular Therapy 2020, 18: 277-287. PMID: 32323590, DOI: 10.1080/14779072.2020.1759422.Peer-Reviewed Original ResearchConceptsAcute ischemic strokeIschemic stroke patientsIschemic strokeStroke patientsTreatment windowAcute ischemic stroke patientsIntravenous tissue plasminogen activatorTreatment ratesUnknown symptom onsetAcute stroke careTissue plasminogen activatorQuality improvement initiativesHealth care resourcesUnited States FoodStroke outcomeSymptom onsetStroke careStroke specialistsStroke systemsTelestroke networkDrug AdministrationAlteplasePatientsPlasminogen activatorStates Food
2018
Forecasting Hepatitis C liver disease burden on real‐life data. Does the hidden iceberg matter to reach the elimination goals?
Kondili LA, Robbins S, Blach S, Gamkrelidze I, Zignego A, Brunetto M, Raimondo G, Taliani G, Iannone A, Russo F, Santantonio T, Zuin M, Chessa L, Blanc P, Puoti M, Vinci M, Erne E, Strazzabosco M, Massari M, Lampertico P, Rumi M, Federico A, Orlandini A, Ciancio A, Borgia G, Andreone P, Caporaso N, Persico M, Ieluzzi D, Madonia S, Gori A, Gasbarrini A, Coppola C, Brancaccio G, Andriulli A, Quaranta M, Montilla S, Razavi H, Melazzini M, Vella S, Craxì A, Group P. Forecasting Hepatitis C liver disease burden on real‐life data. Does the hidden iceberg matter to reach the elimination goals? Liver International 2018, 38: 2190-2198. PMID: 29900654, PMCID: PMC6282782, DOI: 10.1111/liv.13901.Peer-Reviewed Original ResearchConceptsHCV elimination goalsElimination goalsBirth cohortHCV-endemic countriesLiver disease burdenCare scenariosHigh prevalence groupPublic health initiativesEligible patientsAntiviral treatmentPrevalence groupDisease burdenViraemic infectionsBurden estimatesEndemic countriesPatientsCare individualsHealth initiativesAbstractTextTreatment ratesCohortScreening strategyEligible poolTreatmentPotential strategyNeuroimaging Paradigms to Identify Patients for Reperfusion Therapy in Stroke of Unknown Onset
Etherton M, Barreto A, Schwamm L, Wu O. Neuroimaging Paradigms to Identify Patients for Reperfusion Therapy in Stroke of Unknown Onset. Frontiers In Neurology 2018, 9: 327. PMID: 29867736, PMCID: PMC5962731, DOI: 10.3389/fneur.2018.00327.Peer-Reviewed Original ResearchReperfusion therapyIschemic strokeSalvageable ischemic tissueAcute ischemic strokePivotal clinical trialsTreatment of patientsNumber of patientsRisk of infarctionLow treatment ratesUnwitnessed strokeIntravenous alteplaseEndovascular thrombectomyHospital arrivalStroke onsetRevascularization therapySalvageable tissueUnknown onsetClinical trialsClinical dilemmaIschemic tissueStroke researchPatientsTreatment ratesStrokeTherapyDelays in the Air or Ground Transfer of Patients for Endovascular Thrombectomy
Regenhardt RW, Mecca AP, Flavin SA, Boulouis G, Lauer A, Zachrison KS, Boomhower J, Patel AB, Hirsch JA, Schwamm LH, Leslie-Mazwi TM. Delays in the Air or Ground Transfer of Patients for Endovascular Thrombectomy. Stroke 2018, 49: 1419-1425. PMID: 29712881, PMCID: PMC5970980, DOI: 10.1161/strokeaha.118.020618.Peer-Reviewed Original ResearchConceptsEndovascular therapySpoke hospitalsTelestroke networkUnderwent endovascular therapyEndovascular thrombectomyHealth StrokeIschemic strokeClinical outcomesMedian delayHub hospitalInclusion criteriaTelestroke consultsMultivariable regressionTreatment opportunitiesPossible predictorsTreatment ratesPatientsHospitalDaytime transfersLong transfer timesNational Institute
2017
Racial Disparities in Clinically Significant Prostate Cancer Treatment: The Potential Health Information Technology Offers
Bickell N, Lin J, Abramson S, Hoke G, Oh W, Hall S, Stock R, Fei K, McAlearney A. Racial Disparities in Clinically Significant Prostate Cancer Treatment: The Potential Health Information Technology Offers. JCO Oncology Practice 2017, 14: jop.2017.025957. PMID: 29194001, PMCID: PMC5765902, DOI: 10.1200/jop.2017.025957.Peer-Reviewed Original ResearchConceptsTreatment underuseRacial disparitiesBlack menHealth information technology capabilitiesWhite menCancer care qualityPoor quality careInterviewed treating physiciansInformation technology-based solutionsCare qualityQuality careCancer careReduce disparitiesUrban hospitalsProstate cancerRate of prostate cancerUnderuseCareTechnology-based solutionsAge-matched white menTreatment ratesDisparitiesClinically significant prostate cancerHealthSignificant prostate cancer
2016
Adoption of new agents and changes in treatment patterns for hepatitis C: 2010-2014.
Yao X, Sangaralingham LR, Ross JS, Shah ND, Talwalkar JA. Adoption of new agents and changes in treatment patterns for hepatitis C: 2010-2014. The American Journal Of Managed Care 2016, 22: e224-32. PMID: 27355910.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiviral AgentsDatabases, FactualDrug Therapy, CombinationFemaleHealth Care CostsHepacivirusHepatitis C, ChronicHumansInsurance Claim ReviewInterferonsLogistic ModelsMaleMiddle AgedOligopeptidesPredictive Value of TestsRetrospective StudiesRibavirinSofosbuvirTreatment OutcomeUnited StatesConceptsTreatment ratesNew medicationsRetrospective analysisHepatitis C virus medicationsOptum Labs Data WarehouseUS commercial insurance databaseLedipasvir/sofosbuvirMedian OOP costsNew HCV medicationsInterferon/ribavirinInterferon-based regimensCommercial insurance databaseAdministrative claims dataChronic HCVLiver transplantElderly patientsHCV medicationsHepatitis CNew regimensLiver diseaseTreatment patternsInsurance databaseUrgent treatmentPrimary treatmentClaims dataTelestroke—the promise and the challenge. Part two—expansion and horizons
Akbik F, Hirsch J, Chandra R, Frei D, Patel A, Rabinov J, Rost N, Schwamm L, Leslie-Mazwi T. Telestroke—the promise and the challenge. Part two—expansion and horizons. Journal Of NeuroInterventional Surgery 2016, 9: 361. PMID: 26984867, DOI: 10.1136/neurintsurg-2016-012340.Peer-Reviewed Original ResearchConceptsSpecialist careMajor public health concernAcute ischemic strokeTime-sensitive therapiesExamination of patientsUse of telemedicinePublic health concernNovel therapeutic platformIntravenous thrombolysisStroke preventionEndovascular thrombectomyIschemic strokeStroke presentationStroke expertiseTreatment benefitVideo consultationsTreatment ratesHealth concernTelestrokeCarePotential roleStrokeSensitive therapyTherapeutic platformThrombectomyTelestroke—the promise and the challenge. Part one: growth and current practice
Akbik F, Hirsch J, Chandra R, Frei D, Patel A, Rabinov J, Rost N, Schwamm L, Leslie-Mazwi T. Telestroke—the promise and the challenge. Part one: growth and current practice. Journal Of NeuroInterventional Surgery 2016, 9: 357. PMID: 26984868, DOI: 10.1136/neurintsurg-2016-012291.Peer-Reviewed Original ResearchConceptsSpecialist careMajor public health concernAcute ischemic strokeLarge vessel occlusionManagement of patientsTime-sensitive therapiesExamination of patientsUse of telemedicinePublic health concernIntravenous thrombolysisEndovascular thrombectomyIschemic strokeStroke presentationStroke expertiseVessel occlusionTreatment benefitVideo consultationsTreatment ratesHealth concernTelestrokeCurrent practicePatientsStrokeSensitive therapyCare
2015
The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States
Durham DP, Skrip LA, Bruce RD, Vilarinho S, Elbasha EH, Galvani AP, Townsend JP. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States. Clinical Infectious Diseases 2015, 62: 298-304. PMID: 26628566, PMCID: PMC4706637, DOI: 10.1093/cid/civ894.Peer-Reviewed Original ResearchConceptsHepatitis C virusInterferon-free DAAsHCV incidenceTreatment ratesChronic hepatitis C virusCases of cirrhosisInjection drug useImpact of administrationAnnual treatment ratesEnhanced screeningHCV prevalenceHCV screeningDecompensated cirrhosisHCV infectionHCV transmissionHepatitis CLiver transplantActing antiviralsLevels of screeningPatients 4C virusHepatocellular carcinomaEpidemiological dataUniversal screeningDrug useConsumers’ Valuation of Primary Care–Based Treatment Options for Mental and Substance Use Disorders
Epstein AJ, Barry CL, Fiellin DA, Busch SH. Consumers’ Valuation of Primary Care–Based Treatment Options for Mental and Substance Use Disorders. Psychiatric Services 2015, 66: 772-774. PMID: 25930049, PMCID: PMC4523443, DOI: 10.1176/appi.ps.201500077.Peer-Reviewed Original ResearchConceptsUsual careSubstance use disordersUse disordersTreatment optionsSpecialty treatmentMental disordersPrimary care-based treatmentPrimary care settingAlcohol use disorderCare visitsTreatment visitsPrimary careCollaborative careCare settingsTreatment settingsTreatment ratesTreatment typeCareDisordersTreatmentVisitsMost individualsOptionsSettingIndividuals
2013
Characteristics of Adults With Substance Use Disorders Expected to Be Eligible for Medicaid Under the ACA
Busch SH, Meara E, Huskamp HA, Barry CL. Characteristics of Adults With Substance Use Disorders Expected to Be Eligible for Medicaid Under the ACA. Psychiatric Services 2013, 64: 520-526. PMID: 23450343, PMCID: PMC3672321, DOI: 10.1176/appi.ps.201200011.Peer-Reviewed Original ResearchConceptsSubstance use disorder treatmentUse disorder treatmentAffordable Care ActSubstance use disordersDisorder treatmentMedicaid enrolleesUse disordersUnmet needTreatment ratesSignificant unmet needFederal poverty levelCharacteristics of adultsTreatment needsMedicaid coverageDrug useHealth statusUninsured individualsInsurance expansionDemographic characteristicsCare ActDisordersTreatmentNational surveyLow-income individualsInformal careVariation in Receipt of Radiation Therapy After Breast-conserving Surgery
Feinstein AJ, Soulos PR, Long JB, Herrin J, Roberts KB, Yu JB, Gross CP. Variation in Receipt of Radiation Therapy After Breast-conserving Surgery. Medical Care 2013, 51: 330-338. PMID: 23151590, PMCID: PMC3596448, DOI: 10.1097/mlr.0b013e31827631b0.Peer-Reviewed Original ResearchConceptsUse of RTShort life expectancyRadiation therapyBreast cancerLife expectancyPrimary surgeonStage I breast cancerEarly-stage breast cancerRadiation oncologist densityAdjuvant radiation therapyI breast cancerReceipt of radiationBreast-conserving surgeryImpact of physiciansHierarchical logistic regression modelsLogistic regression modelsLonger life expectancyLE patientsRetrospective cohortLE groupOlder womenPatientsTreatment ratesWomenCancer
2012
Predictors of Male Partner Treatment for Sexually Transmitted Infection
Secura G, Desir F, Mullersman J, Madden T, Allsworth J, Peipert J. Predictors of Male Partner Treatment for Sexually Transmitted Infection. Sexually Transmitted Diseases 2012, 39: 769-775. PMID: 23001263, PMCID: PMC3457019, DOI: 10.1097/olq.0b013e31825ec611.Peer-Reviewed Original ResearchConceptsPartner treatmentSTI testingTreatment ratesMale partner treatmentRobust error varianceLongitudinal cohort studyPatient-specific factorsInconsistent condom useCharacteristics of womenContraceptive CHOICE ProjectFuture STIsCohort studyIndependent predictorsPartner notificationStudy clinicMultivariable analysisAntibiotic treatmentUnivariate analysisCost contraceptionSex partnersTreatment dataPoisson regressionCondom useMale partnersBaseline surveyEmergency Medical Service Hospital Prenotification Is Associated With Improved Evaluation and Treatment of Acute Ischemic Stroke
Lin C, Peterson E, Smith E, Saver J, Liang L, Xian Y, Olson D, Shah B, Hernandez A, Schwamm L, Fonarow G. Emergency Medical Service Hospital Prenotification Is Associated With Improved Evaluation and Treatment of Acute Ischemic Stroke. Circulation Cardiovascular Quality And Outcomes 2012, 5: 514-522. PMID: 22787065, DOI: 10.1161/circoutcomes.112.965210.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBrain IschemiaCommunicationEmergency Medical ServicesEmergency Service, HospitalFemaleFibrinolytic AgentsGuideline AdherenceHealth Services AccessibilityHospitalsHumansLogistic ModelsMaleMiddle AgedMultivariate AnalysisOutcome and Process Assessment, Health CarePractice Guidelines as TopicQuality ImprovementRegistriesStrokeThrombolytic TherapyTime FactorsTime-to-TreatmentTissue Plasminogen ActivatorTreatment OutcomeUnited StatesConceptsAcute ischemic strokeTissue plasminogen activatorNeedle timeEMS prenotificationHospital prenotificationIschemic strokeEligible patientsShorter doorIntravenous tissue plasminogen activatorClustering of patientsShorter symptom onsetQuality of careGuidelines-StrokeTPA useSymptom onsetPotential strokeStroke treatmentPatientsPoisson regressionStrokeTreatment ratesIncoming patientsGreater likelihoodPrenotificationMinutes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply